Home › NDC Lookup › RxCUI directory › RxCUI 2724413

Paltusotine 30 MG Oral Tablet [Palsonify] — RxCUI 2724413

RxNorm drug concept · Semantic branded drug
RxCUI 2724413 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2724413
Official namePaltusotine 30 MG Oral Tablet [Palsonify]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asPalsonify 30 MG Oral Tablet; Palsonify 30 MG Oral Tablet, Once Daily; Palsonify 30 MG (equivalent to paltusotine hydrochloride 32.4 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Paltusotine 30 MG Oral Tablet [Palsonify] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Paltusotine 30 MG Oral Tablet [Palsonify] RxCUI 2724413

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Paltusotine 2724363
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Palsonify 2724404
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Paltusotine Oral Tablet 2724402
    • Paltusotine Oral Product 2724400
    • Paltusotine Pill 2724401
    • Paltusotine Oral Tablet [Palsonify] 2724408
    • Palsonify Oral Product 2724406
    • Palsonify Pill 2724407
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Paltusotine 30 MG Oral Tablet SCD · 2724411
  • Paltusotine 30 MG SCDC · 2724410
  • Paltusotine Oral Tablet SCDF · 2724402
  • Paltusotine Oral Product SCDG · 2724400
  • Paltusotine Pill SCDG · 2724401

Brand-Name Concepts

  • Paltusotine 30 MG [Palsonify] SBDC · 2724412
  • Paltusotine Oral Tablet [Palsonify] SBDF · 2724408
  • Palsonify Oral Product SBDG · 2724406
  • Palsonify Pill SBDG · 2724407
  • Palsonify BN · 2724404

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2724413 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
84015-0920-60 60 TABLET, FILM COATED in 1 BOTTLE (84015-920-60) PALSONIFY Crinetics Pharmaceuticals, Inc. 2025-09-25
84015-0930-60 60 TABLET, FILM COATED in 1 BOTTLE (84015-930-60) PALSONIFY Crinetics Pharmaceuticals, Inc. 2025-09-25
Observed labelers: Crinetics Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.